近期亨迪药业（301211）发布2025年中报，证券之星财报模型分析如下： 经营业绩概览 从主营业务构成来看，非甾体抗炎类产品收入为1.6亿元，占总收入的68.06%，毛利率为15.27%；心血 管类产品收入为3776.06万元，占总收入的16.08%，毛利率高达71.83%；其他类产品收入为2080.97万 元，占总收入的8.86%，毛利率为8.44%；抗肿瘤类产品收入为1641.92万元，占总收入的6.99%，毛利率 为-11.32%。 发展回顾与展望 报告期内，公司研发投入为15,876,209.56元，较上年同期下降17.72%。公司取得了布洛芬缓释胶囊、托 拉塞米注射液和布洛芬混悬液的《药品注册证书》，并在多个项目上取得进展。此外，公司全资子公司 武汉百科药物通过了FDA cGMP现场检查，公司再次获得高新技术企业认定。 总体来看，亨迪药业在2025年上半年面临较大的经营压力，业绩下滑显著，费用激增拖累了盈利能力。 未来，公司需要进一步优化成本结构，提升产品毛利率，以恢复盈利水平。 公司的毛利率为21.9%，同比减少了39.16%；净利率为7.9%，同比减少了72.1%。每股收益为0.06元， 同比 ...

Group 1: Financial Performance - In 2024, the company's revenue was CNY 445,864,331.31, a decrease of 32.75% compared to the previous year [2][3] - The net profit attributable to shareholders was CNY 91,547,379.78, down 48.02% year-on-year [2][3] Group 2: Research and Development - In 2024, the company invested CNY 32,937,088.26 in R&D and reported one Chinese invention patent [2] - The company has obtained several drug registration certificates, including for ibuprofen sustained-release capsules and tolvaptan injection [3] Group 3: Future Plans - The company aims to reduce production costs and enhance market competitiveness through technological upgrades [3] - A new R&D center in Wuhan has been established to accelerate the development of a CDMO one-stop service platform [3] Group 4: Shareholder Engagement - The company currently has no plans for share buybacks but will disclose any future plans in accordance with regulations [2] - The company actively engages with investors through online platforms for Q&A sessions [2]

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]